Predicting Disease Severity of Necrotizing Enterocolitis: How to Identify Infants for Future Novel Therapies

Troy A. Markel, Holly Engelstad1, Brenda B. Poindexter1
Departments of Surgery, Section of Pediatric Surgery, and Pediatrics, Section of Neonatology, Riley Hospital for Children at Indiana University Health, Indiana University School of Medicine, Indianapolis, Indiana, USA

ABSTRACT
Necrotizing enterocolitis (NEC) remains a very devastating problem within the very low birth weight neonatal population. Several experimental therapies are being tested in animal models and soon may be ready for human trials. Despite this progress, we currently have no way to identify infants who would be optimal targets for therapy. Specifically, we are unable to predict which infants will progress to the more severe Bell’s stage of disease that may necessitate surgery. Ideally, an algorithm could be constructed that would encompass multiple neonatal and maternal risk factors as well as potential biologic markers of disease so that these infants could be identified in a more timely fashion. This review summarizes the known risk factors and biomarkers of disease in hopes of stimulating clinical research to identify such an “early warning” NEC algorithm.

Key words: Biomarkers, necrotizing enterocolitis, neonate, predictors, risk

INTRODUCTION
Necrotizing enterocolitis (NEC) remains one of the most devastating intra-abdominal emergencies in the newborn infant, particularly those of low birth weight.1 Medical management of the more severe cases of NEC is often inadequate, thereby warranting surgical resection of necrotic bowel. In many cases, however, surgical resection leaves the infant with a suboptimal length of intestine that inhibits appropriate nutritional absorption. Therefore, these infants usually require long-term parenteral nutrition and are exposed to the risks and side effects of this therapy. Active research is underway to understand the mechanisms associated with the intestinal ischemia, bacterial translocation, sepsis and organ failure often associated with NEC.1,3

In order to optimize the utility of novel future therapies, it becomes necessary to be able to identify at risk infants before the progression of disease so that therapeutic intervention can be delivered before surgical resection of the bowel is required. Repeated attempts to identify clinical parameters that would reliably identify infants with NEC most likely to progress to severe disease have thus far been unsuccessful.1,4,5 Several previous studies utilizing the Score of Neonatal Acute Physiology and the Metabolic Derangement Acuity score have failed to be able to accurately predict surgical NEC.6 Whereas some studies have claimed to be able to predict surgical NEC based on several laboratory parameters, these have been most notable in small studies and have not been reproducible on a larger scale.7

In view of the high morbidity and mortality associated with surgical NEC, early detection of ischemic or necrotic bowel before surgical intervention could potentially improve outcomes. Identifying specific maternal and neonatal risk factors as well as biomarkers for surgical NEC may aid in creating a predictive algorithm for at-risk infants. Therefore, the purpose of this review is to identify predictive characteristics, including neonatal, maternal, radiographic and biologic factors that may be able facilitate early prediction of surgical NEC so that novel treatment modalities can be effectively implemented.

NEONATAL RISK FACTORS
There are several neonatal risk factors for developing NEC that have been very consistent throughout the literature. These include prematurity, enteral formula feeding and incomplete gastrointestinal colonization by bacteria. Additional factors that may contribute to NEC
NEC is most prevalent in premature infants of very low birth weight. With an inverse relationship between postmenstrual age and incidence of NEC, only 7-15% of all NEC cases occur in term or late preterm infants. More than 85% of cases occur in infants <1500 g or <32 weeks gestational age. This translates to an incidence of approximately 11-15% in the very low birth weight population as determined by the National Institute of Child Health and Human Development Neonatal Research Network. Several contributing factors of NEC may be related to intestinal prematurity, including immature intestinal peristalsis, which may allow bacteria to adhere and translocate more easily. Additional factors include decreased or different intestinal mucous production, increased intestinal permeability, decreased gastric acid production, immature proteolytic enzymes, and immature gut hormones and enzymes for digesting enteral nutrition.

Formula feedings are well-known to be an independent risk factor for the development of NEC. Formula feeds may contribute to disease incidence in that they have higher levels of free fatty acids, which are toxic to cells. Formulas also lack a number of beneficial factors including secretory IgA, lysozyme and platelet activating factor acetylhydrolase, which may serve to protect the intestine during times of stress. However, delaying the introduction of progressive enteral feeds does not appear to affect the risk of developing NEC. There are no data from randomized trials of formula milk versus maternal breast milk for feeding preterm and/or low birth weight neonates. However, there are several randomized controlled trials comparing human donor breast milk to formula. A meta-analysis of these trials showed that preterm infants fed with formula had twice the incidence of NEC as compared to those receiving donor milk, although only one study utilized human milk fortifier in the donor milk group, a practice that is commonly used today. Additional data would suggest that there is a dose-related benefit of human milk intake. In a retrospective analysis of the National Institute of Child Health and Human Development Neonatal Network Glutamine Trial, researchers noted that for each 10% increase in the proportion of human milk consumption, the incidence of NEC was lower by a factor of 0.83. In another study, only 3% of infants who received more than 50% as human milk developed NEC, whereas 10% of infants who received <50% of their total enteral intake as human milk developed NEC.

Other recent studies have targeted blood transfusions and have proposed that red blood cell transfusion may be an independent risk factor for developing NEC in the premature infant population. This phenomenon, a variant of Transfusion Associated Gut Injury, has been called Transfusion Associated Necrotizing Enterocolitis (TANEC). The etiology is felt to be immunologic, possibly through alterations of mesenteric arterial reactivity and nitric oxide pathways. Approximately 25-40% of infants who developed NEC were found to have received a blood transfusion within 48 h of disease onset. In addition, infants who were being fed in the 48 h period prior to transfusion were eight times more likely to develop NEC than infants who were neither fed nor transfused. A 2012 meta-analysis of 12 studies clearly demonstrated an association between NEC and transfusion, however a cause and effect relationship has yet to be established. Neonates who developed TANEC were younger by 1.5 weeks, were 500 g lower in birth weight, were more likely to have a patent ductus arteriosus and were more likely to be receiving ventilator support. Some institutions have now developed protocols to limit transfusions in this population and to ensure that enteral feedings do not occur at the time of blood transfusions.

Racial and gender disparities are likely related to genetic variations in these populations. Genetic risk factors associated with NEC have previously not been well-characterized. Nonetheless, it certainly seems intuitive that variations in the genetic code may predispose certain individuals to NEC. Many of the genetic variations noted are single nucleotide polymorphisms (SNPs), which involve the transition of one nucleotide to another nucleotide. Most of the variations occur in non-coding sequences with only about 2-3% being found in the promoter regions or coding exons of the gene. Genetic variations in toll-like receptor (TLR) signaling have been explored since this receptor has been shown to play an important role in disease onset. SNPs in TLR2, TLR4, TLR5, TLR9, IRAK1 and TIRAP genes did not appear to be associated with NEC.
However, variations in NFKB1, and NFKBIA were associated with NEC. Further studies have examined genetic variations in other growth factors and cytokines that may predispose to NEC. These include but are not limited to vascular endothelial growth factor, interleukin (IL)-12, IL-18 and IL-4 receptor alpha.

Certain physiologic parameters have also been implicated as potential risk factors for NEC. A U.S. study examining a database of over 15,000 neonates demonstrated a positive correlation between the number of days of mechanical ventilation and the development of NEC. A possible etiology could be colonization of the respiratory track and bacterial overgrowth associated with intubation. They also saw a positive relationship between the incidence of NEC and use of antenatal glucocorticoids, absence of an umbilical artery catheter, postnatal use of glucocorticoids or indomethacin, low Apgar scores at 5 min and vaginal delivery. Another study also independently appreciated that premature infants who required increased respiratory support to maintain oxygenation during the early neonatal period were 13 times more likely to develop NEC. When combined with lack of breast milk feeds, the likelihood of NEC increased 28.6 times compared with the controls.

The onset of NEC is undoubtedly multifactorial and a discussion of infant risk factors would not be complete without mentioning the intestinal microbiome. Although there is little doubt that microbes play a vital role in the development of NEC, the identity of specific causative pathogens has not been identified. Additional suggestions that intestinal microbes play a significant role in disease pathogenesis come from data demonstrating the benefit and decreased incidence of NEC with the use of supplemental probiotics. However, at this time, there is no predictive assay or factor to determine if an individual's intestinal microbiome puts them at risk for the development of NEC.

One potential correlation between incidence of NEC and bacterial infections was seen between the number of nosocomial infections that infants incurred in the neonatal period and the development of NEC. Frequent infections may decrease the native immune response of the infant, making them more susceptible to pathogens. Vulnerability to infection may also be a result of overuse of antibiotics and the creation of drug resistant bacterial strains, or to the breakdown of native defense mechanisms such as may be seen by increasing gastric pH through the use of histamine-blocker therapy.

MATERNAL RISK FACTORS

The maternal variables that contribute to fetal development and correlate with NEC are not well-defined. As we are currently unable to accurately predict the incidence of NEC in neonates, many investigators have turned to studying these maternal risk factors. A recent study examined plausible maternal risk factors and correlated them to the development of NEC. Maternal smoking, hypertension, diabetes, body mass index, type of delivery and conduct of labor were among the variables inspected. Maternal cigarette smoking was the only maternal risk factor that significantly correlated with the development of NEC.

Maternal exposures to antibiotics and steroids in the prenatal period have also been postulated as potential antecedents to the development of NEC. The neonatal microbiome is greatly dependent on the maternal vaginal and gastrointestinal flora. Maternal broad spectrum antibiotic exposure may alter this native flora which may then place the infant at increased risk for the development of NEC. Administration of antibiotics for the antenatal management of pregnancy complications such as premature rupture of membranes, preterm labor, or chorioamnionitis is common in clinical practice. A few studies have suggested a correlation between maternal exposure of amoxicillin/clavulinate and the development of NEC, while other studies have not found such an association. The data for antenatal steroid use is also controversial, as several studies noted no significant increase in the incidence of NEC associated with prenatal use of steroids, while a much larger study did appreciate a correlation.

Placental pathology has also been felt to contribute to the onset of NEC. One study examined over 5000 placentas from high risk pregnancies and discovered that placentas from infants with surgically treated NEC had significant evidence of vascular pathology such as placental infarcts. In addition, evidence of placental infection (chorioamnionitis or villitis) plus evidence of a fetal inflammatory response were more readily present in placentas from infants with surgical NEC when compared with unaffected infants. Another study found no correlation with placental pathology and NEC, but the population of this study was small and was confined to a single institution.

The belief that abnormal placental vascular resistance can contribute to the predisposition of NEC is quite legitimate. The theory is that placental resistance causes a centralized diversion of blood flow from the splanchnic mesentry. In a multi-institutional U.S. study examining 404 neonates, infants with NEC had statistically higher umbilical artery Doppler indices prenatally, 5 min Apgars <7 and higher umbilical cord artery base deficit. NEC was also more likely with a combined variable consisting of umbilical artery absent or reversed end diastolic velocity, absent or reversed ductus venosus a-wave, or umbilical vein pulsations. Additional studies examined uterine...
artery Doppler waveforms. In 83% of infants with NEC in a single study, there were noted bilateral uterine artery protodiastolic notches and a mean resistance index greater than the 95th percentile. In addition, within the fetus, there was noted absent or retrograde diastolic blood flow through the aortic isthmus. All these parameters would suggest increased placental vascular resistance and associated splanchnic shunting away from the intestinal mesentry.

**RADIOGRAPHIC PREDICTORS**

The modified Bell’s stage is currently the most noted classification scheme in existence for NEC. The scale is based entirely on broad clinical and radiographic findings and is not specific for NEC, nor is it predictive of disease severity. In fact, some investigators feel that these staging criteria should be abandoned and other alternative methods to identify NEC embraced. The seminal paper by Bell et al., used a combination of radiographic and bedside clinical criteria to gauge the severity of NEC. Over time, it has gone well beyond just staging criteria and has become essential to the capture and reporting of infants with NEC. It was later modified to distinguish between perforated and non-perforated NEC.

The main imaging modality that has been used to identify progression of disease has been the abdominal plain film. Despite its frequent use, individual radiographic signs of NEC do not readily correlate with disease severity. The presence of multiple signs, however, may increase radiographic predictability. In one study, investigators described the sensitivity and specificity for pneumatosis intestinalis (44% and 100%, respectively), portal venous gas (13% and 100%), free air (52% and 92%) and a gasless abdomen (32% and 92%, respectively).

A recent study of radiographic findings crafted a numeric score designed to indicate relative certainty that a patient was progressing in severity of NEC. This scale was termed the Duke abdominal assessment scale (DAAS). It is a 10 point scale that progresses from 0, or “normal gas pattern”, through “fixed or persistent dilation of bowel loops”, to a score of 10 which is indicative of “pneumoperitoneum”. This study noted increasing DAAS scores with increasing disease severity and noted that patients were more likely to undergo operative intervention with every one point increase in DAAS score.

Ultrasonography has become an added adjunct to the radiographic evaluation of neonates suspected of having NEC. Echogenic dots and dense granular echogenicities can often be found in infants with early stage NEC. A recent study examining 44 neonates who had 55 sonograms correlated ultrasound findings to radiographic imaging and clinical outcomes. Focal fluid collections, echogenic free fluid (likely debris), increased bowel wall echogenicity and bowel wall thickness were statistically significant for predicting unfavorable outcomes. Conversely, anechoic free peritoneal fluid predicted a good outcome.

In some instances where perforation was present in the absence of free intraperitoneal air, ultrasound was able to detect echoic free fluid and bowel wall thickening. The sensitivity of free air at abdominal radiography as a positive sign for surgical NEC with perforation is about 40%, whereas there can be 100% sensitivity by appreciating the absence of color flow during ultrasound. Despite its added utility, the quality and accuracy of ultrasound imaging is extremely operator dependent. In addition, many centers do not have ultrasound capabilities within the facility 24 h a day, which may also limit its diagnostic utility.

**BIOLOGICAL MARKERS**

As previously mentioned, clinical parameters alone have been inadequate in predicting progression to surgical NEC. Many investigators are therefore suggesting that a variety of biologic markers be investigated. Identifying a specific biomarker or panel of biomarkers may allow for physicians to detect severe cases of NEC before operative intervention is required. Ideal biomarkers should be able to differentiate NEC from sepsis and should also increase with severity of NEC.

A recent study from Hong Kong examined three intestinal biomarkers, liver-fatty acid binding protein, which is expressed by enterocytes and hepatocytes, intestinal fatty acid binding protein (I-FABP), which is expressed solely by enterocytes and trefoil factor 3, which is expressed in the mucus-producing epithelial cells and goblet cells. In this particular study, all three factors, as well as the combined value, known as the LIT score, were significantly higher in the NEC groups when compared with septicemia or control groups. These biomarkers and the LIT score were also higher in NEC non-survivors compared with survivors. A LIT score >4.5 identified surgical NEC with a sensitivity of 83% and specificity of 100%.

Studies looking at infants with Bell’s stage II/III NEC were observed to have higher levels of I-FABP to creatinine ratios with increasing severity of disease. In addition, I-FABP: Cr ratios decreased after successful non-operative management as well as after surgery. Other studies confirmed the utility of the use of I-FABP and saw that I-FABP levels were elevated in those necessitating surgery or who succumbed to NEC when compared to conservatively treated patients. Urinary I-FABP levels were only useful
Once a clinical suspicion was made, however and may not be an adequate screening tool for NEC. A 2012 prospective multicenter study assessed another potential biomarker, S100 myeloid related protein (S100 A8/A9), a key player in the innate immune response. The authors concluded that this marker was significantly elevated in infants with surgical NEC when compared to those with sepsis or controls. They defined the optimal cutoff value at 3.0 mg/ml by a receiver operating characteristic curve analysis. With this assay they maintained a sensitivity of 100%, specificity of 96.4%, positive predictive value of 88.9% and negative predictive value of 100%. Due to its accuracy, the S100 A8/A9 levels may be a promising tool to detect subclinical NEC.

Fecal concentrations of S100A12, a marker of intestinal inflammation, were also assessed. In a prospective study of 145 preterm infants, SA100A12 was significantly higher in infants with severe NEC at the onset of disease and at 4-10 days prior to onset. Unfortunately, the sensitivity and specificity were fairly low at 76% and 56% respectively. Other fecal markers, including lactoferrin and calprotectin have also been studied with mixed enthusiasm. Both are inflammatory markers of gastrointestinal disease. In a small study of 14 newborns with NEC and 63 healthy infants, there were no noted differences in fecal concentrations of lactoferrin or calprotectin. However, others found that calprotectin could actually serve as a biomarker if corrected for gestational age. Sensitivity and specificity for distinguishing moderate NEC from healthy infants and those with intestinal distress was fairly high with this correction.

Other serum markers, such as C-reactive protein (CRP), serum amyloid A (SAA) and procalcitonin have been studied as potential biomarkers for the diagnosis and follow up of NEC. These markers may serve to distinguish advanced disease as opposed to screening, as infants with NEC stages II and III were significantly higher than those with only sepsis or stage I disease. Negative levels of CRP might indicate another process, such as ileus. A recent multi-institution, multiyear retrospective study of 220 neonates with Bell’s stage two or greater found that CRP was significantly elevated 3 days prior to diagnosis in infants with stage three disease. In addition, these infants were more likely to have a higher immature to total neutrophil ratio, as well as lower platelet count and pH. In another study, SAA was higher in NEC infants than controls, but significantly lower in NEC infants when compared to those with sepsis. When inspected separately, the SAA levels of stage II NEC were higher than controls and stage I NEC, but similar to those with sepsis. This may indicate that SAA is not a suitable biomarker to distinguish NEC from sepsis, but may be used to show progression of disease once diagnosed.

Inflammatory and anti-inflammatory cytokines have been extensively studied in the pathogenesis of NEC. Many cytokines are also elevated in neonatal sepsis which makes utilizing them as biomarkers for NEC somewhat difficult. Nonetheless, a few cytokines, including IL-8 and IL-6 may be useful in detecting severity of disease. Studies assaying IL-8 have been able to differentiate the degree of bowel involvement in NEC. A cutoff of 449 pg/ml provided specificity of 82% and sensitivity of 83% in discriminating focal from multifocal and panintestinal disease. Likewise, a cutoff of 1388 pg/ml had specificity and sensitivity of 78% and 77% respectively for discriminating panintestinal disease from multifocal and focal disease. IL-6 may also be a useful cytokine biomarker. A study done by Harris et al., found that IL-6 levels were elevated 5-10 fold in infants with bacterial sepsis plus NEC, as compared to infants with sepsis alone or controls. This study also noted that IL-6 levels were higher in non-survivors of NEC, indicating that IL-6 elevations are related to increased mortality.

Examination of the umbilical cord has also been considered to identify infants at risk for NEC. The theory is that infants have inefficient antioxidant systems and are unable to counteract the harmful effects of free radicals. An Italian study recruited 332 patients at three European neonatal intensive care units. They saw that cord blood levels of several markers of oxidative stress, non-protein bound iron, advanced oxidation protein products and total hydroperoxides were significantly increased in babies with NEC compared to healthy babies.

Vital sign and bioimpedence monitoring may be effective alternatives to traditional serum or fecal biologic markers. Abnormal heart rate characteristics have previously been implemented as a biomarker for sepsis and neonatal mortality. In a randomized clinical trial involving over 3000 patients, heart rate characteristic monitoring significantly reduced mortality in very low birth weight infants. Reduced heart rate variability and transient decelerations often occur in preclinical sepsis and may be applicable in NEC. In a 2013 U.S. study, investigators found that patients who developed surgical NEC had significantly higher baseline heart rate characteristic indices 1-3 days before diagnosis. Likewise, at the time of diagnosis, infants with surgical NEC had higher indices.

Ideally, it would be beneficial to screen the infant's mother in the antenatal period for discrepancies in various biomarkers or immune modulators so as to be able to predict and prepare for the problem in the infant. Some have inspected the same biomarkers in the mother that they
have inspected in the infants. A U.S. study assayed maternal levels of IL-6, CRP and matrix metalloproteinase-9 between 24 and 32 weeks gestation in order to determine if elevations in these biomarkers could predict preterm labor or neonatal morbidity. Elevations in these markers above the 90th percentile were associated with preterm birth at gestational ages <32 weeks. There was no correlation however, between these levels and the development of NEC.\cite{101}

A very recent study published in Gut combined clinical parameters with analysis of several urinary biomarkers, namely a family of fibrinogen peptides and found that the combination of parameters and biomarkers into an “ensemble algorithm” greatly increased the clinician's ability to predict the severity of NEC. Authors noted that prior to utilizing the ensemble that 40% of patients were not able to be accurately predicted. With the combination of parameters, all patients with surgical NEC were able to be appropriately categorized. This study utilized a small cohort from a larger population of individuals with NEC and certainly needs to be verified on a larger scale.\cite{102}

Based on the available literature, there are clearly a number of serum, fecal and physiologic biomarkers exist that may be able to assist in readily identifying infants with NEC. Identifying the appropriate cut-off values between normal, septic and NEC infants will be paramount in identifying appropriate screening assays for NEC. In addition, identifying a panel of biomarkers will likely increase the sensitivity above any single test and may allow for a timelier implementation of novel therapies.

**CONCLUSION**

Surgically treated NEC can be very devastating. Surviving infants require attentive healthcare and often need invasive catheters for parenteral nutrition. Our current ability to medically treat NEC is limited. There are currently new therapies in development,\cite{103-107} which have the potential to limit the extent of disease if administered before its deleterious effects. A scoring system to predict surgical NEC to limit the extent of disease if administered before its deleterious effects. A scoring system to predict surgical NEC to limit the extent of disease if administered before its deleterious effects. A scoring system to predict surgical NEC to limit the extent of disease if administered before its deleterious effects. A scoring system to predict surgical NEC to limit the extent of disease if administered before its deleterious effects. A scoring system to predict surgical NEC to limit the extent of disease if administered before its deleterious effects. A scoring system to predict surgical NEC to limit the extent of disease if administered before its deleterious effects. A scoring system to predict surgical NEC to limit the extent of disease if administered before its deleterious effects. A scoring system to predict surgical NEC to limit the extent of disease if administered before its deleterious effects.

**REFERENCES**

1. Markel TA, Crisostomo PR, Wairuku GM, Pitcher J, Tsai BM, Meldrum DR. Cytokines in necrotizing enterocolitis. Shock 2006;25:329-37.
2. Neal MD, Leaphart C, Levy R, Prince J, Billiar TR, Watkins S, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006;176:3070-9.
3. Ayala A, Song GY, Chung CS, Redmond KM, Chaudry IH. Immune depression in polymicrobial sepsis: The role of necrotic (injured) tissue and endotoxin. Crit Care Med 2000;28:3949-55.
4. Moss RL, Kalish LA, Duggan C, Johnston P, Brandt ML, Dunn JC, et al. Clinical parameters do not adequately predict outcome in necrotizing enterocolitis: A multi-institutional study. J Perinatol 2008;28:665-74.
5. Upperman JS, Camerini V, Lugo B, Yotov I, Sullivan J, Rubin J, et al. Mathematical modeling in necrotizing enterocolitis – A new look at an ongoing problem. J Pediatr Surg 2007;42:445-53.
6. Ibáñez V, Couselo M, Marijuan V, Vilaj J, García-Sala C. Could clinical scores guide the surgical treatment of necrotizing enterocolitis? Pediatr Surg Int 2012;28:271-6.
7. Gupta SK, Burke G, Herson VC. Necrotizing enterocolitis: Laboratory indicators of surgical disease. J Pediatr Surg 1994;29:1472-5.
8. Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med 2011;364:255-64.
9. Sharma R, Hudak ML, Tepas JJ 3rd, Whudyka PS, Marvin WJ, Bradshaw JA, et al. Impact of gestational age on the clinical presentation and surgical outcome of necrotizing enterocolitis. J Perinatol 2006;26:342-7.
10. Sharma R, Hudak ML. A clinical perspective of necrotizing enterocolitis: Past, present, and future. Clin Perinatol 2013;40:27-51.
11. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Lattopok AR, Welsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126:443-56.
12. Yee WH, Soraisham AS, Shah VS, Aziz K, Yoon W, Lee SK, et al. Incidence and timing of presentation of necrotizing enterocolitis in preterm infants. Pediatrics 2012;129:e308-304.
13. Berseth CL. Gestational evolution of small intestine motility in preterm and term infants. J Pediatr 1989;115:646-51.
14. Clauw EC. Neonatal Necrotizing Enterocolitis-Inflammation and intestinal immaturity. Antiinflamm Antiallergy Agents Med Chem 2009;8:248-59.
15. Snyder JD, Walker WA. Structure and function of intestinal mucin: Developmental aspects. Int Arch Allergy Appl Immunol 1987;82:351-6.
16. Rouwet EV, Heineman E, Buurman WA, ter Riet G, Ramsay G, Blanco CE. Intestinal permeability and carrier-mediated monosaccharide absorption in preterm neonates during the early postnatal period. Pediatr Res 2002;51:64-70.
17. Udall JN Jr. Gastrointestinal host defense and necrotizing enterocolitis. J Pediatr 1990;117 (1 Pt 2):S33-43.
18. Lebenthal A, Lebenthal E. The ontogeny of the small intestinal epithelium. JPEN J Parenter Enteral Nutr 1999;23:53-6.
19. Penn AH, Alshuler AE, Small JW, Taylor SF, Dobkirs KR, Schmid-Schönbein GW. Digested formula but not digested fresh human milk causes death of intestinal cells in vitro: Implications for necrotizing enterocolitis. Pediatr Res 2012;72:560-70.
20. Ramani M, Ambalavanan N. Feeding practices and necrotizing enterocolitis. Clin Perinatol 2013;40:1-10.
21. Paul DA, Mackley A, Novitsky A, Zhao Y, Brooks A, Locke RG. Increased odds of necrotizing enterocolitis after transfusion of red blood cells in premature infants. Pediatrics 2011;127:635-41.
22. Morgan J, Bombell S, McGuire W. Early trophic feeding versus enteral fasting for very preterm or very low birth weight infants. Cochrane Database Syst Rev 2013;3:CD000504.
23. Henderson G, Anthony MY, McGuire W. Formula milk versus maternal breast milk for feeding preterm or low birth weight infants. Cochrane Database Syst Rev 2007;4:CD002972.
24. Quigley MA, Henderson G, Anthony MY, McGuire W. Formula milk versus donor breast milk for feeding preterm or low birth weight infants. Cochrane Database Syst Rev 2007;4:CD002971.
25. Meinzen-Derr J, Poindeexter B, Wrage L, Morrow AL, Stoll B, Donovan EE. Role of human milk in extremely low birth weight infants’ risk of necrotizing enterocolitis or death. J Perinatol 2009;29:57-62.

26. Sisk PM, Lovelady CA, Dillard RG, Gruber KJ, O’Shea TM. Early human milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. J Perinatol 2007;27:428-33.

27. Wan-Huen P, Bateman D, Shapiro DM, Parravicini E. Packed red cell blood transfusion is an independent risk factor for necrotizing enterocolitis in premature infants. J Perinatol 2013;33:786-90.

28. Bak SY, Lee S, Park JH, Park KH, Jeon JH. Analysis of the association between necrotizing enterocolitis and transfusion of red blood cell in very low birth weight preterm infants. Korean J Pediatr 2013;56:112-5.

29. Demirel G, Celik IH, Aksoy HT, Erdeve O, Oguz SS, Uras N, et al. Transfusion-associated necrotising enterocolitis in very low birth weight premature infants. Transfus Med 2012;22:332-7.

30. Nair J, Gugino SF, Nielsen LC, Allen C, Russell JA, Mathew B, et al. Packed red cell transfusions alter mesenteric arterial reactivity and nitric oxide pathway in preterm lambs. Pediatr Res 2013;74:452-7.

31. Amin SC, Remon JJ, Subbarao GC, Maheshwari A. Association between red cell transfusion and necrotizing enterocolitis. J Matern Fetal Neonatal Med 2012;25:85-9.

32. Mohamed A, Shah PS. Transfusion associated necrotizing enterocolitis: A meta-analysis of observational data. Pediatrics 2012;129:529-40.

33. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007;196:417-8.

34. Carter BM, Holditch-Davis D. Risk factors for necrotizing enterocolitis in preterm infants: How race, gender, and health status contribute. Adv Neonatal Care 2008;8:285-90.

35. Uauy RD, Fanaroff AA, Korones SB, Phillips EA, Phillips JB, Wright LL. Necrotizing enterocolitis in very low birth weight infants: Biodemographic and clinical correlates. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1991;119:630-8.

36. Treszl A, Tulassay T, Vásárhelyi B. Genetic basis for necrotizing enterocolitis. J Perinatol 2012;32:529-40.

37. Sampath V, Le M, Lane L, Patel AL, Cohen JN, Siddall PM, et al. The NFκB1 (g.-24159delATTG) variant is associated with necrotizing enterocolitis (NEC) in premature infants. J Surg Res 2011;169:251-7.

38. Bányázs I, Bokodi G, Vásárhelyi B, Treszl A, Derzsbach L, Szabó A, et al. Genetic polymorphisms for vascular endothelial growth factor in perinatal complications. Eur Cytokine Netw 2006;17:266-70.

39. Bokodi G, Derzsbach L, Bányázs I, Tulassay T, Vásárhelyi B. Association of interferon gamma T+874A and interleukin 12 p40 promoter CTCTTAA/GC polymorphism with the need for respiratory support and perinatal complications in low birthweight neonates. Arch Dis Child Fetal Neonatal Ed 2007;92:F25-9.

40. Treszl A, Héninger E, Kalmán A, Schuler A, Tulassay T, Vásárhelyi B. Lower prevalence of IL-4 receptor alpha-chain gene G variant in very-low-birth-weight infants with necrotizing enterocolitis. J Pediatr Surg 2013;48:374-9.

41. Guthrie SO, Gordon PV, Thomas V, Thorp JA, Peabody J, Clark RH. Necrotizing enterocolitis among neonates in the United States. J Perinatol 2003;23:278-85.

42. Gregory KE. Clinical predictors of necrotizing enterocolitis in premature infants. Nurs Res 2008;57:260-70.

43. Grishin A, Papillon S, Bell B, Wang J, Ford HR. The role of the intestinal microbiota in the pathogenesis of necrotizing enterocolitis. Semin Pediatr Surg 2013;22:69-75.

44. Mai V, Young CM, Ukhanova M, Wang X, Sun Y, Casella G, et al. Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS One 2011;6:e20647.

45. Downard CD, Renaud E, St Peter SD, Abdullah F, Islam S, Saito JM, et al. Treatment of necrotizing enterocolitis: An American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg 2012;47:2111-22.

46. Bernardo WM, Aires FT, Carneiro RM, SA FP, Rullo VE, Burns DA. Effectiveness of probiotics in the prophylaxis of necrotizing enterocolitis in preterm neonates: A systematic review and meta-analysis. J Pediatr (Rio J) 2013;39:18-24.

47. Ganguli K, Meng D, Rautava S, Lu L, Walker WA, Nanthakumar N. Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. Am J Physiol Gastrointest Liver Physiol 2013;304:G132-41.

48. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sánchez PJ, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009;123:58-66.

49. Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006;117:e137-42.

50. Carrion V, Egan EA. Prevention of neonatal necrotizing enterocolitis. J Pediatr Gastroenterol Nutr 1990;11:317-23.

51. Downard CD, Grant SN, Maki AC, Krupski MC, Matheson PJ, Bendon RW, et al. Maternal cigarette smoking and the development of necrotizing enterocolitis. Pediatrics 2012;129:607-11.

52. Claude EC, Walker WA. Hypothesis: Inappropriate colonization of the premature intestine can cause neonatal necrotizing enterocolitis. FASEB J 2001;15:1398-403.

53. Harnsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, Klijn N, Bindels JG, et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr 2000;30:617.

54. Bonnemaison E, Lanotte P, Cantagrel S, Thiouin S, Quentin R, Chamboux C, et al. Comparison of fecal flora following administration of two antibiotic protocols for suspected maternal-fetal infection. Biol Neonate 2003;84:304-10.

55. Hällström M, Eerola E, Vuento R, Janas M, Tammela O. Effects of mode of delivery and necrotising enterocolitis on the intestinal microbiota in preterm infants. Eur J Clin Microbiol Infect Dis 2004;23:461-70.

56. Hoy C, Millar MR, MacKay P, Godwin PG, Langdale V, Levene MJ. Quantitative changes in faecal microflora preceding necrotising enterocolitis in premature neonates. Arch Dis Child 1990;65:1057-9.

57. Jacquot A, Neveu D, Aujoulat F, Mercier G, Marchand H, Jumas-Bilak E, et al. Dynamics and clinical evolution of bacterial gut microflora in extremely premature patients. J Pediatr 2011;158:390-6.

58. Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: The ORACLE I randomised trial. ORACLE Collaborative Group. Lancet 2001;357:979-88.

59. Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group. Broad-spectrum antibiotics for spontaneous preterm labour: The ORACLE II randomised trial. ORACLE Collaborative Group. Lancet 2001;357:989-94.

60. Weintraub AS, Ferrara L, Deluca L, Moshier E, Green RS, Oakman E, et al. Antenatal antibiotic exposure in preterm infants with necrotizing enterocolitis. J Perinatol 2012;32:705-9.

61. Ehsanipoor RM, Chung JH, Clock CA, McNulty JA, Wing DA. A retrospective review of ampicillin-sulbactam and amoxicillin-clavulanate vs cefazolin/cephalexin and erythromycin in the setting of preterm premature rupture of membranes: Maternal and neonatal outcomes. Am J Obstet Gynecol 2008;198:654-6.
62. Mercer BM, Miodownik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 1997;278:989-95.

63. Romejko-Wolniewicz E, Oleszczuk L, Zareba-Szczudlik J, Czajkowski K. Dosage regimen of antenatal steroids prior to preterm delivery and effects on maternal and neonatal outcomes. J Matern Fetal Neonatal Med 2013;26:237-41.

64. Arroyo Cabrales LM, Guzmán Bárcenas I. Prenatal steroids for fetal maturation in preterm birth. Experience at an institution. Ginecol Obstet Mex 2000;68:448-52.

65. Smith LM, Qureshi N, Chao CR. Effects of single and multiple courses of antenatal glucocorticoids in preterm newborns less than 30 weeks' gestation. J Matern Fetal Med 2009;131-5.

66. Moore SW, Arnold M, Wright C. Necrotizing enterocolitis and the placenta—a key etiological link. J Pediatr Surg 2013;48:559-62.

67. Been JV, Lievens E, Zimmermann LJ, Kramer BW, Wolfs TG. Chorioamnionitis as a risk factor for necrotizing enterocolitis: A systematic review and meta-analysis. J Pediatr 2013;162:236-42.

68. Hackett GA, Campbell S, Gamsu H, Cohen-Overbeek T, Pearce JM. Doppler studies in the growth retarded fetus and prediction of neonatal necrotising enteroenteritis, haemorrhage, and neonatal morbidity. Br J Clin Res Ed 1987;294:1-6.

69. McDonnell M, Serra-Serra V, Gaffney G, Redman CW, Hope PL. Neonatal outcome after pregnancy complicated by abnormal velocity waveforms in the umbilical artery. Arch Dis Child Fetal Neonatal Ed 1994;70:F84-9.

70. Achiron R, Orvieto R, Lipitz S, Rotstein Z, Superior mesenteric artery blood flow velocimetry: Cross-sectional Doppler sonographic study in normal fetuses. J Ultrasound Med 1998;17:769-73.

71. Baschat AA, Gemburc U, Reiss I, Görtner L, Weiner CR, Harman CR. Relationship between arterial and venous Doppler and perinatal outcome in fetal growth restriction. Ultrasound Obstet Gynecol 2000;16:407-13.

72. Manogura AC, Turan O, Kush ML, Berg C, Bhide A, Turan S, et al. Predictors of necrotizing enterocolitis in preterm growth-restricted neonates. Am J Obstet Gynecol 2008;198:683.e1-5.

73. Raboison MJ, Huissoud C, Lapointe A, Hugues N, Bigras JL, Brassard M, et al. Assessment of uterine artery and aortic isthmus Doppler recordings as predictors of necrotizing enterocolitis. Am J Obstet Gynecol 2012;206:321.e1-6.

74. Gordon PV, Swanson JR, Attridge JT, Clark R. Emerging trends in acquired neonatal intestinal disease: Is it time to abandon Bell's criteria? J Perinatol 2007;27:661-71.

75. Kliegman RM, Walsh MC. Neonatal necrotizing enterocolitis: Pathogenesis, classification, and spectrum of illness. Curr Probl Pediatr 1987;17:123-88.

76. Di Napoli A, Di Lallo D, Perucci CA, Schifano P, Orzalesi M, Franco F, et al. Inter-observer reliability of radiological signs of necrotising enterocolitis in a population of high-risk newborns. Paediatr Perinat Epidemiol 2004;18:80-7.

77. Rehan VK, Seshia MM, Johnston B, Reed M, Wilmot D, Cook V. Observer variability in interpretation of abdominal radiographs of infants with suspected necrotizing enterocolitis. Clin Pediatr (Phila) 1999;38:637-43.

78. Tam AL, Camberos A, Applebaum H. Surgical decision making in necrotizing enterocolitis and focal intestinal perforation: Predictive value of radiologic findings. J Pediatr Surg 2002;37:1688-91.

79. Coursey CA, Hollingsworth CL, Gaca AM, Maxfield C, Delong D, Bisset G 3rd. Radiologists' agreement when using a 10-point scale to report abdominal radiographic findings of necrotizing enterocolitis in neonates and infants. AJR Am J Roentgenol 2008;191:190-7.

80. Coursey CA, Hollingsworth CL, Wriston C, Beam C, Rice H, Bisset G 3rd. Radiographic predictors of disease severity in neonates and infants with necrotizing enterocolitis. AJR Am J Roentgenol 2009;193:1408-13.

81. Muchantef K, Epelman M, Darge K, Kirpalani H, Laje P, Anupindi SA. Sonographic and radiographic imaging features of the neonate with necrotizing enterocolitis: Correlating findings with outcomes. Pediatr Radiol 2013;43:1444-52.

82. Dilli D, Suna Oğuz S, Erol B, Özkan-Ulu H, Dumanlı H, Dilmen U. Does abdominal sonography provide additional information over abdominal plain radiography for diagnosis of necrotizing enterocolitis in neonates? Pediatr Surg Int 2011;27:321-7.

83. Faingold R, Daneman A, Tomlinson G, Babyn PS, Mанс DE, Mohanta A, et al. Necrotizing enterocolitis: Assessment of bowel viability with color doppler US. Radiology 2005;235:578-94.

84. Ng EW, Poon TC, Lam HS, Cheung HM, Ma TP, Chan KY, et al. Gut-associated biomarkers L-FABP, I-FABP, and TFF3 and LIT score for diagnosis of surgical necrotizing enterocolitis in preterm infants. Ann Surg 2013;258:1111-8.

85. Evennett NJ, Hall NJ, Pierro A, Eaton S. Urinary intestinal fatty acid-binding protein concentration predicts extent of disease in necrotizing enterocolitis. J Pediatr Surg 2010;45:735-40.

86. Thuils G, Derikx JP, van Wijck K, Zimmermann LJ, Degrauw PE, Mulder TL, et al. Non-invasive markers for early diagnosis and determination of the severity of necrotizing enterocolitis. Ann Surg 2010;251:1174-80.

87. Terrin G, Passariello A, De Curtis M, Paludetto R, Berni Canani R. S100A8/A9 protein as a marker for early diagnosis of necrotising enterocolitis in neonates. Arch Dis Child 2012;97:1102.

88. Däbritz J, Jenke A, Wirth S, Foell D. Fecal phagocyte-specific S100A12 for diagnosing necrotizing enterocolitis. J Pediatr 2012;161:1059-64.

89. Selimoğlu MA, Temel I, Yıldırım C, Özylan F, Aktaş M, Karabiber B. The role of fecal calprotectin and lactoferrin in the diagnosis of necrotizing enterocolitis. Pediatr Crit Care Med 2012;13:452-4.

90. Zoppelli L, Güttel C, Bittrich HJ, Andréé C, Wirth S, Jenke A. Fecal calprotectin concentrations in premature infants have a lower limit and show postnatal and gestational age dependence. Neonatology 2012;102:68-74.

91. Cetinkaya M, Ozkan H, Köksal N, Akaci O, Ozgür T. Comparison of the efficacy of serum amyloid A, C-reactive protein, and procalcitonin in the diagnosis and follow-up of necrotizing enterocolitis in premature infants. J Pediatr Surg 2011;46:1482-9.

92. Pourcours M, Korones SB, Yang W, Boulden TF, Bada HS. C-reactive protein in the diagnosis, management, and prognosis of neonatal necrotizing enterocolitis. Pediatrics 2005;116:1084-9.

93. Miner CA, Fullmer S, Eggert DL, Christensen RD. Factors affecting the severity of necrotizing enterocolitis. J Matern Fetal Neonatal Med 2013;26:1715-9.

94. Eras Z, Oğuz S, Dizdar EA, Sari FN, Dilmen U. Serum amyloid-A levels in neonatal necrotizing enterocolitis. J Clin Lab Anal 2011;25:233-7.

95. Benkoe T, Reck C, Gleiss A, Kettner S, Repa A, Horcher E, et al. Interleukin 8 correlates with intestinal involvement in surgically treated infants with necrotizing enterocolitis. J Pediatr Surg 2012;47:1548-54.

96. Harris MC, Costantino AT Jr, Sullivan JS, Dulkarian S, McCawley L, Corcoran L, et al. Cytokine elevations in critically ill infants with sepsis and necrotizing enterocolitis. J Pediatr Surg 1999;34:105-11.

97. Perrone S, Tatarrano ML, Negro S, Cornacchione S, Longini M, Proietti E, et al. May oxidative stress biomarkers in cord blood predict the occurrence of necrotizing enterocolitis in preterm infants? J Matern Fetal Neonatal Med 2012;25:Suppl 1:128-31.

98. Griffin MP, Lake DE, Bissonette EA, Harrell FE Jr, O’Shea TM, Moorman JR. Heart rate characteristics: Novel physiometers to predict neonatal infection and death. Pediatrics 2005;116:1070-4.
99. Moorman JR, Carlo WA, Kattwinkel J, Schelonka RL, Porcelli PJ, Navarrete CT, et al. Mortality reduction by heart rate characteristic monitoring in very low birth weight neonates: A randomized trial. J Pediatr 2011;159:900-61.

100. Stone ML, Tatum PM, Weitkamp JH, Mukherjee AB, Attridge J, McGahren ED, et al. Abnormal heart rate characteristics before clinical diagnosis of necrotizing enterocolitis. J Perinatol 2013;33:847-50.

101. Sorokin Y, Romero R, Mele L, Wapner RJ, Iams JD, Dudley DJ, et al. Maternal serum interleukin-6, C-reactive protein, and matrix metalloproteinase-9 concentrations as risk factors for preterm birth<32 weeks and adverse neonatal outcomes. Am J Perinatol 2010;27:531-40.

102. Sylvester KG, Ling XB, Liu GY, Kastenberg ZJ, Ji J, Hu Z, et al. A novel urine peptide biomarker-based algorithm for the prognosis of necrotising enterocolitis in human infants. Gut 2013; Sep 18. [Epub ahead of print].

103. Radulescu A, Zhang HY, Yu X, Olson JK, Darbyshire AK, Chen Y, et al. Heparin-binding epidermal growth factor-like growth factor overexpression in transgenic mice increases resistance to necrotizing enterocolitis. J Pediatr Surg 2010;45:1933-9.

104. Markel TA, Crisostomo PR, Lahn T, Novotny NM, Rescorla FJ, Tector J, et al. Stem cells as a potential future treatment of pediatric intestinal disorders. J Pediatr Surg 2008;43:1953-63.

105. Tayman C, Uckan D, Kilic E, Ulus AT, Tonbul A, Murat Hirfanoglu I, et al. Mesenchymal stem cell therapy in necrotizing enterocolitis: A rat study. Pediatr Res 2011;70:489-94.

106. Zani A, Cananzi M, Fascetti-Leon F, Lauriti G, Smith VV, Bollini S, et al. Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism. Gut 2014;63:300-9.

107. Yang J, Watkins D, Chen CL, Bhushan B, Zhou Y, Besner GE. Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis. J Am Coll Surg 2012;215:534-45.

How to cite this article: Markel TA, Engelstad H, Poindexter BB. Predicting disease severity of necrotizing enterocolitis: How to identify infants for future novel therapies. J Clin Neonatol 2014;3:1-9.

Source of Support: Nil, Conflict of Interest: None declared.